Related references
Note: Only part of the references are listed.Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle
Liisa Hantsoo et al.
NEUROBIOLOGY OF STRESS (2020)
Allopregnanolone and reproductive psychiatry: an overview
Katherine McEvoy et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2019)
Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder
M. Bixo et al.
JOURNAL OF NEUROENDOCRINOLOGY (2018)
Startling Differences: Using the Acoustic Startle Response to Study Sex Differences and Neurosteroids in Affective Disorders
Liisa Hantsoo et al.
CURRENT PSYCHIATRY REPORTS (2018)
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
Samantha Meltzer-Brody et al.
LANCET (2018)
Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial
Marie Bixo et al.
PSYCHONEUROENDOCRINOLOGY (2017)
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback
T. V. Nguyen et al.
TRANSLATIONAL PSYCHIATRY (2017)
Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels
Peter J. Schmidt et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS)
Tory A. Eisenlohr-Moul et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study
Erika Timby et al.
PSYCHOPHARMACOLOGY (2016)
Women with PTSD have a changed sensitivity to GABA-A receptor active substances
Anna Tiihonen Moller et al.
PSYCHOPHARMACOLOGY (2016)
Women with polycystic ovary syndrome have elevated serum concentrations of and altered GABAA receptor sensitivity to allopregnanolone
Helena Hedstrom et al.
CLINICAL ENDOCRINOLOGY (2015)
Elevation of brain allopregnanolone rather than 5-HT release by short term, low dose fluoxetine treatment prevents the estrous cycle-linked increase in stress sensitivity in female rats
Adam J. Devall et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans
Sara K. S. Bengtsson et al.
PSYCHONEUROENDOCRINOLOGY (2015)
Premenstrual Dysphoric Disorder: Epidemiology and Treatment
Liisa Hantsoo et al.
CURRENT PSYCHIATRY REPORTS (2015)
Allopregnanolone in the bed nucleus of the stria terminalis modulates contextual fear in rats
Naomi Nagaya et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2015)
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder A Randomized Clinical Trial
Kimberly A. Yonkers et al.
JAMA PSYCHIATRY (2015)
Allopregnanolone and mood disorders
T. Backstrom et al.
PROGRESS IN NEUROBIOLOGY (2014)
Reliability of the Timeline Followback for Cocaine, Cannabis, and Cigarette Use
Sean M. Robinson et al.
PSYCHOLOGY OF ADDICTIVE BEHAVIORS (2014)
SSRIs and the female brain - potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias
Thelma Lovick
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Increased neurosteroid sensitivity - An explanation to symptoms associated with chronic work related stress in women?
Torbjorn Backstrom et al.
PSYCHONEUROENDOCRINOLOGY (2013)
Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5
C. Neill Epperson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2012)
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome
Ellen W. Freeman et al.
CONTRACEPTION (2012)
RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER
Emma M. Steinberg et al.
DEPRESSION AND ANXIETY (2012)
Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test)
Anja Schmitz et al.
NATURE PROTOCOLS (2012)
Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics
Steven M. Pincus et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2011)
Phasic and sustained fear in humans elicits distinct patterns of brain activity
Ruben P. Alvarez et al.
NEUROIMAGE (2011)
S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice
Marianela Nelson et al.
NEUROPHARMACOLOGY (2011)
PARADOXICAL EFFECTS OF GABA-A MODULATORS MAY EXPLAIN SEX STEROID INDUCED NEGATIVE MOOD SYMPTOMS IN SOME PERSONS
T. Backstrom et al.
NEUROSCIENCE (2011)
Histories of major depression and premenstrual dysphoric disorder: Evidence for phenotypic differences
Rebecca R. Klatzkin et al.
BIOLOGICAL PSYCHOLOGY (2010)
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Michael Davis et al.
NEUROPSYCHOPHARMACOLOGY (2010)
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake
Graziano Pinna et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Allopregnanolone Levels Before and After Selective Serotonin Reuptake Inhibitor Treatment of Premenstrual Symptoms
Clarisa R. Gracia et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Two-Week Treatment With the Selective Serotonin Reuptake Inhibitor Citalopram Reduces Contextual Anxiety but Not Cued Fear in Healthy Volunteers: A Fear-Potentiated Startle Study
Christian Grillon et al.
NEUROPSYCHOPHARMACOLOGY (2009)
The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women
S. Gehlert et al.
PSYCHOLOGICAL MEDICINE (2009)
Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled trial in Canadian women
Meir Steiner et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder
Elias Eriksson et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder
Cynthia Neill Epperson et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder
Mikael Landen et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?
Uriel Halbreich et al.
CNS DRUGS (2006)
Daily Record of Severity of Problems (DRSP): reliability and validity
J Endicott et al.
ARCHIVES OF WOMENS MENTAL HEALTH (2005)
Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone
DJ Toufexis et al.
JOURNAL OF NEUROSCIENCE (2004)
Role of the bed nucleus of the stria tenninalis versus the amygdala in fear, stress, and anxiety
DL Walker et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study
EW Freeman et al.
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE (2002)
Share Paper
